SS-31 and eye health: what the dry AMD trial actually showed

Key takeaways

• SS-31 (elamipretide) was tested in 176 adults with advanced dry AMD for 48 weeks.
• The trial missed both of its main vision goals.
• It did slow damage to the retina's light-sensing cells by about 43%, a secondary finding.
• That's a promising signal, not proof of better eyesight. Phase 3 is running now.

SS-31 keeps showing up in eye-health conversations online, usually with someone saying it "helped their vision." There is a real clinical trial behind the hype. It just doesn't say what most of the posts claim it says.

Here's the plain-English version of what was tested, what worked, and what didn't.

Why anyone thought SS-31 might help the eyes

The retina is one of the most energy-hungry tissues in the body. Its light-sensing cells (photoreceptors) run on mitochondria, and as those mitochondria age and falter, the cells start to die off. That's part of how dry age-related macular degeneration (AMD) progresses ¹.

SS-31, sold as a prescription drug under the name elamipretide, is a peptide that binds to the inner membrane of mitochondria and is thought to stabilize them ². The idea was simple: if retinal cells are failing because their power supply is failing, a mitochondria-targeted drug might slow the damage. Worth noting that elamipretide is now an FDA-approved drug, but for Barth syndrome, a rare mitochondrial muscle disease, not for anything to do with the eyes ²³.

What the ReCLAIM-2 trial did

ReCLAIM-2 was a Phase 2, randomized, placebo-controlled trial run at multiple U.S. sites ¹. It enrolled 176 people aged 55 and up with dry AMD and geographic atrophy, which is the advanced stage where patches of retina have already died. 117 got a daily 40 mg injection of elamipretide under the skin; 59 got placebo. Treatment ran 48 weeks.

The trial had two main goals: improve how well people see in low light, and slow the growth of the dead patch on the retina.

What it found

It missed both main goals. Neither low-light vision nor the growth of the atrophy patch was significantly different from placebo ¹.

What it did find was in a secondary measure. The drug slowed the loss of the ellipsoid zone, a layer on retinal scans that reflects photoreceptor health. Total loss of that layer progressed 43% slower on elamipretide than on placebo (nominal p=0.003), and partial degradation was 47% slower ¹.

There was also a small vision signal. About 14.6% of treated patients gained 10 or more letters of low-light acuity, versus a much smaller share on placebo ¹. That reached statistical significance, but it's a secondary endpoint in a small group, which means it needs confirming before anyone leans on it.

Safety looked acceptable. Injection-site reactions were the main complaint, which matches what's been seen with the drug elsewhere ¹³.

What that means in practice

Slower photoreceptor loss is a real and interesting result. Photoreceptor damage shows up on scans before the atrophy patch grows, so it's a plausible early marker of where the disease is headed ¹. The FDA has agreed it can be used as a primary endpoint, and Stealth BioTherapeutics has moved into Phase 3 trials using exactly that measure ¹⁴.

But it is a stand-in measurement, not vision. The trial was built to show better eyesight and slower atrophy, and it didn't. A structural marker moving in the right direction is a reason to run a bigger trial. It is not a reason to say the drug improves vision.

The bro science review

The common claim: "Everyone online says it helped their eyes."

The reality: the one controlled trial that exists shows the vision endpoints failed. People reporting improvement after injecting a research-grade peptide, with no placebo group and no eye exam, are reporting an experience, not evidence. The part that gets left out of every social post is the missed primary endpoint, and that's the part that matters most.

Anyone with vision changes needs an eye professional, not a peptide forum. Dry AMD is diagnosable and monitorable, and the earlier it's caught the more options there are.

The bottom line

SS-31 has a real but unproven signal in advanced dry AMD: it slowed photoreceptor loss in one Phase 2 trial, while missing its actual vision goals. Phase 3 will tell us whether that structural effect turns into something people can see. Until then, claims that it improves eyesight are running ahead of the data.

This is educational information, not medical advice.

Sources

1. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation — Ophthalmology Science, January 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11599447
2. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome — U.S. Food and Drug Administration, September 19, 2025. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
3. Forzinity (elamipretide) prescribing information — FDA, September 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf
4. ReCLAIM-2 Shows Potential of Elamipretide for Geographic Atrophy in Dry AMD — HCPLive. https://hcplive.com/view/reclaim-2-shows-potential-of-elamipretide-for-geographic-atrophy-in-dry-amd